

# Myt1 Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP58072

## Product Information

---

|                                |  |
|--------------------------------|--|
| <b>Application</b>             | WB, IHC-P, IHC-F, IF, E  |
| <b>Primary Accession</b>       | <a href="#">Q01538</a>   |
| <b>Reactivity</b>              | Rat, Dog, Bovine   |
| <b>Host</b>                    | Rabbit   |
| <b>Clonality</b>               | Polyclonal   |
| <b>Calculated MW</b>           | 122329   |
| <b>Physical State</b>          | Liquid   |
| <b>Immunogen</b>               | KLH conjugated synthetic peptide derived from human Myt1   |
| <b>Epitope Specificity</b>     | 541-640/1121   |
| <b>Isotype</b>                 | IgG  |
| <b>Purity</b>                  | affinity purified by Protein A   |
| <b>Buffer</b>                  | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.  |
| <b>SUBCELLULAR LOCATION</b>    | Nucleus.   |
| <b>SIMILARITY</b>              | Contains 7 C2HC-type zinc fingers.   |
| <b>SUBUNIT</b>                 | nteracts with STEAP3.  |
| <b>Important Note</b>          | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.  |
| <b>Background Descriptions</b> | Myt1 is a zinc finger protein that is known to interact with the co-repressor Sin3B and also HDAC1 and HDAC2. The Myt1 family, including Myt1 and Myt1L, exemplifies a class of neural sequence specific transcription factors that actively recruit HDACs to selected genes during CNS development. |

## Additional Information

---

|                           |   |
|---------------------------|---|
| <b>Gene ID</b>            | 4661  |
| <b>Other Names</b>        | Myelin transcription factor 1, MyT1, Myelin transcription factor I, MyTI, PLPB1, Proteolipid protein-binding protein, MYT1, KIAA0835, KIAA1050, MTF1, MYTI, PLPB1                                     |
| <b>Target/Specificity</b> | Mostly in developing nervous system. Expressed in neural progenitors and oligodendrocyte lineage cells. More highly expressed in oligodendrocyte progenitors than in differentiated oligodendrocytes. |
| <b>Dilution</b>           | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000   |
| <b>Format</b>             | 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce  |
| <b>Storage</b>            | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody   |

is stable for at least two weeks at 2-4 °C.


## Protein Information

---

|                          |  |
|--------------------------|--|
| <b>Name</b>              | MYT1   |
| <b>Synonyms</b>          | KIAA0835, KIAA1050, MTF1, MYTI, PLPB1  |
| <b>Function</b>          | Binds to the promoter region of genes encoding proteolipid proteins of the central nervous system. May play a role in the development of neurons and oligodendroglia in the CNS. May regulate a critical transition point in oligodendrocyte lineage development by modulating oligodendrocyte progenitor proliferation relative to terminal differentiation and up-regulation of myelin gene transcription. |
| <b>Cellular Location</b> | Nucleus.   |
| <b>Tissue Location</b>   | Mostly in developing nervous system. Expressed in neural progenitors and oligodendrocyte lineage cells. More highly expressed in oligodendrocyte progenitors than in differentiated oligodendrocytes.  |

## Images

---



Paraformaldehyde-fixed, paraffin embedded (Mouse placenta); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Myt1) Polyclonal Antibody, Unconjugated (AP58072) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.